Logo image of CBUS

CIBUS INC (CBUS) Stock Fundamental Analysis

NASDAQ:CBUS - US17166A1016 - Common Stock

1.26 USD
0 (0%)
Last: 9/5/2025, 12:45:01 PM
Fundamental Rating

2

CBUS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. CBUS may be in some trouble as it scores bad on both profitability and health. CBUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CBUS had negative earnings in the past year.
In the past year CBUS has reported a negative cash flow from operations.
In the past 5 years CBUS always reported negative net income.
In the past 5 years CBUS always reported negative operating cash flow.
CBUS Yearly Net Income VS EBIT VS OCF VS FCFCBUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -79.53%, CBUS is doing worse than 67.34% of the companies in the same industry.
Looking at the Return On Equity, with a value of -381.75%, CBUS is doing worse than 74.54% of the companies in the same industry.
Industry RankSector Rank
ROA -79.53%
ROE -381.75%
ROIC N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
CBUS Yearly ROA, ROE, ROICCBUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBUS Yearly Profit, Operating, Gross MarginsCBUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CBUS has been increased compared to 1 year ago.
The number of shares outstanding for CBUS has been increased compared to 5 years ago.
CBUS has a better debt/assets ratio than last year.
CBUS Yearly Shares OutstandingCBUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CBUS Yearly Total Debt VS Total AssetsCBUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

CBUS has an Altman-Z score of -3.75. This is a bad value and indicates that CBUS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CBUS (-3.75) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.
CBUS has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACC9.89%
CBUS Yearly LT Debt VS Equity VS FCFCBUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.78 indicates that CBUS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.78, CBUS is doing worse than 78.41% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that CBUS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.78, CBUS is not doing good in the industry: 77.31% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
CBUS Yearly Current Assets VS Current LiabilitesCBUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.86% over the past year.
Looking at the last year, CBUS shows a very strong growth in Revenue. The Revenue has grown by 63.39%.
The Revenue for CBUS have been decreasing by -10.20% on average. This is quite bad
EPS 1Y (TTM)86.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.49%
Revenue 1Y (TTM)63.39%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%11.34%

3.2 Future

Based on estimates for the next years, CBUS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.85% on average per year.
The Revenue is expected to grow by 137.38% on average over the next years. This is a very strong growth
EPS Next Y4.06%
EPS Next 2Y24.09%
EPS Next 3Y19.6%
EPS Next 5Y20.85%
Revenue Next Year19.32%
Revenue Next 2Y39.31%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CBUS Yearly Revenue VS EstimatesCBUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CBUS Yearly EPS VS EstimatesCBUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBUS Price Earnings VS Forward Price EarningsCBUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBUS Per share dataCBUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CBUS's earnings are expected to grow with 19.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.09%
EPS Next 3Y19.6%

More info and screens

0

5. Dividend

5.1 Amount

CBUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIBUS INC

NASDAQ:CBUS (9/5/2025, 12:45:01 PM)

1.26

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-05 2025-11-05
Inst Owners24.59%
Inst Owner Change4.93%
Ins Owners32.86%
Ins Owner Change63.37%
Market Cap68.34M
Analysts80
Price Target14.69 (1065.87%)
Short Float %3.55%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.91%
Min EPS beat(2)-9.92%
Max EPS beat(2)13.74%
EPS beat(4)2
Avg EPS beat(4)24.36%
Min EPS beat(4)-12.97%
Max EPS beat(4)106.57%
EPS beat(8)2
Avg EPS beat(8)-93.21%
EPS beat(12)4
Avg EPS beat(12)-138.57%
EPS beat(16)7
Avg EPS beat(16)-98.59%
Revenue beat(2)0
Avg Revenue beat(2)-15.64%
Min Revenue beat(2)-20.19%
Max Revenue beat(2)-11.09%
Revenue beat(4)2
Avg Revenue beat(4)35.33%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)167.48%
Revenue beat(8)6
Avg Revenue beat(8)64.47%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.06%
PT rev (3m)-15.73%
EPS NQ rev (1m)23.79%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-6.94%
Revenue NQ rev (1m)9.74%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-9.91%
Revenue NY rev (3m)-11.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.1
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.09
BVpS1.33
TBVpS-3.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.53%
ROE -381.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.46%
ROA(5y)-69.14%
ROE(3y)-199.52%
ROE(5y)-185.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.15%
Cap/Sales 16.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -3.75
F-Score5
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)67.73%
Cap/Depr(5y)64.06%
Cap/Sales(3y)402.26%
Cap/Sales(5y)243.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.49%
EPS Next Y4.06%
EPS Next 2Y24.09%
EPS Next 3Y19.6%
EPS Next 5Y20.85%
Revenue 1Y (TTM)63.39%
Revenue growth 3Y-45.26%
Revenue growth 5Y-10.2%
Sales Q2Q%11.34%
Revenue Next Year19.32%
Revenue Next 2Y39.31%
Revenue Next 3Y178.77%
Revenue Next 5Y137.39%
EBIT growth 1Y10.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.08%
EBIT Next 3Y29.53%
EBIT Next 5Y22.72%
FCF growth 1Y-131.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-136.37%
OCF growth 3YN/A
OCF growth 5YN/A